MiMedx Group, Inc (NASDAQ:MDXG)

  • Projektion von James on Yahoo Board

    Below are my sales and fair value estimates that I posted a few months back for the next 36 and 48 months. The sales forecast is a run rate… which means the monthly sales for 12/31/20 will be 29.16 per month…. After the third quarter, my forecast has not changed… As of today, my MDXG fair value is in a band of $10 to 12 per share… To maximize our returns and minimize the risk in this position, I would advise extending your horizon to a minimum of 12 to 18 months…. Although the stock has 250 million is sales roughly……. It is going to take some time to rebuild the US sales team, expand marketing internationally, and to get FDA approval for the injectables…. Although my forecast seems aggressive… they may prove conservative once new products get the FDA go ahead….. Just forget this stock for a while… this is a 7 to 10 bagger….

    James the Accountant…

    12/31/20 350m, $15, by 2/21

    12/31/21 500m, $25 by 2/22

    12/31/23 1000, $50 by 2/24

  • Aktuell $11.34


    MiMedx Announces Last Patients Last Visits in Three Late-Stage Musculoskeletal Trials with Proprietary Tissue Technology Advances Potential for Use of Micronized Dehydrated Human Amnion Chorion Membrane (mdHACM) as a Safe and Effective Treatment Option On Track to Advance Planned Analyses and Announce Top-Line Data in Plantar Fasciitis, Achilles Tendonitis and Knee Osteoarthritis in Q3 2021

    MARIETTA, Ga., April 19, 2021 — MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that the last patients have completed their last clinical visits in two late-stage Investigational New Drug (IND) trials: Phase 3 studies of AmnioFixInjectable (micronized dehydrated Human Amnion Chorion Membrane (mdHACM)) as a potential treatment for Plantar Fasciitis and Achilles Tendonitis. In addition, all clinical effectiveness endpoint visits have been completed in a Phase 2B study of mdHACM as a potential treatment for Knee Osteoarthritis. With the completion of these patient visits, the Company will begin the planned review and statistical analyses of data from all three trials. “Completion of the Phase 2B study for mdHACM as a treatment for Knee Osteoarthritis marks an extraordinary milestone,” said Alfred Gellhorn, M.D., Adjunct Associate Professor of Clinical Rehabilitation and Director of Sports Medicine, Weill Cornell Medicine. “There is a tremendous unmet need for safe and effective treatment options for Knee Osteoarthritis. The osteoarthritis community has long recognized that current treatment options are painfully insufficient. The benefit of a novel therapeutic option in this setting for both patients and clinicians cannot be overstated.”

  • Up we go

    MIMEDX Receives Regulatory Approval To Commercialize EPIFIX® In Japan

    June 8, 2021 at 8:30 AM EDT

    Availability of EPIFIX Allografts Expected Early 2022

    Approval Makes it Possible to Bring EPIFIX’s Healing Properties to as Many as 100,000 New Patients Annually

    MARIETTA, Ga., June 08, 2021 (GLOBE NEWSWIRE) -- MIMEDX Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced successful regulatory approval by the Japanese Ministry of Health, Labour and Welfare (JMHLW) to market EPIFIX® in Japan.

    EPIFIX - a bioabsorbable, human amniotic membrane allograft, is applied to affected areas for wound healing. The product uses proprietary methods, including the PURION® process, to provide a semi-permeable, protective barrier that supports the healing cascade. EPIFIX protects the wound bed to aid in the development of granulation tissue and delivers a human biocompatible extracellular matrix that retains 300+ regulatory proteins.

    MIMEDX submitted a Shonin (pre-market approval) to the JMHLW, Japan’s primary regulatory body for creating and implementing safety standards for drugs and medical devices, and the Pharmaceutical and Medical Device Agency (PMDA), an independent administrative agency that works with JMHLW to ensure the safety and quality of drugs and medical devices, in mid-2020. EPIFIX was approved for hard-to-heal chronic wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs), which do not respond to conventional therapy. EPIFIX will be classified as a Class IV Medical Device and “Specified Biological Product” under JMHLW guidelines.

    Dr. Hiroto Terashi, Chief Professor in Department of Plastic Surgery at Kobe University, Chairman of the Japanese Society for Foot Care and Podiatric Medicine (JFCPM), and Chairman of the Japan Society for Surgical Wound Care (JSSWC) said, “As a plastic surgeon and wound care physician for my entire career, I am delighted with EPIFIX’s approval in Japan. EPIFIX will greatly expand treatment options for chronic wounds caused by lower extremity venous and diabetic ulcers in patients in Japan, providing opportunities for increased limb salvage.”

    "Diabetic foot ulcers and venous leg ulcers that are unable to heal on their own pose a serious long-term health risk to people around the world. Our vision is to provide access to EPIFIX technology that can change people’s lives, no matter where they live,” said Stan Micek, MIMEDX Senior Vice President, Business Development and International. “We are extremely pleased with JMHLW’s decision to grant Shonin approval for EPIFIX, and we are glad to be one step closer to bringing EPIFIX to market in Japan. Our focus will now shift toward obtaining appropriate reimbursement and establishing logistical and distribution networks for commercialization, which we hope will result in full availability of EPIFIX in the Japanese market in early 2022.”

    The Company is currently working with JMHLW to establish reimbursement pricing, a process expected to take up to six months. Once a reimbursement pricing policy is approved and the reimbursement rate is listed, the Company can begin offering EPIFIX to patients and providers in Japan.

    Timothy R. Wright, MIMEDX Chief Executive Officer, commented, “EPIFIX can only benefit patients with hard-to-heal wounds if they can access its life-improving properties, and regulatory approval is a significant milestone in addressing unmet need for people in Japan. With today’s announcement, EPIFIX now has the potential to reach as many as 100,000 additional patients each year. This critical step helps us fulfil our mission of bringing advanced regenerative medicine to suffering patient populations and is important in the Company’s global expansion.”

    Important Cautionary Statement

    This press release includes forward-looking statements, including among other things, statements regarding: (i) expectations about the classification of EPIFIX as a Class IV Medical Device and “Specified Biological Product” under JMHLW guidelines; (ii) expectation that EPIFIX will greatly expand treatment options for chronic wounds caused by lower extremity venous and diabetic ulcers in patients in Japan; and (iii) the Company’s expectations regarding the approval of a reimbursement pricing policy for EPIFIX in Japan and the timeline for availability of EPIFIX in the Japanese market. Additional forward-looking statements may be identified by words such as "believe," "expect," "may," "plan," "potential," "will," "preliminary," and similar expressions, and are based on management's current beliefs and expectations.

    Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause actual results to differ from expectations include: (i) the Company may change its plans due to unforeseen circumstances, and delay or alter the timeline for future trials, analyses, or public announcements; (ii) the timing of any meeting with or decision by JMHLW depends on many factors and the availability and timing of such a meeting or decision is outside of the Company’s control; and (iii) reimbursement pricing approval requires the satisfaction of various conditions; is often subject to detailed rules; and the timing, amount, and final approval decision rests with the JMHLW. The Company describes additional risks and uncertainties in the Risk Factors section of its most recent annual report and quarterly reports filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and the Company assumes no obligation to update any forward-looking statement

  • Ab Stocktwits.com, MDXG, User Bemelord12

    This is James the Accountant. These are my revised forecast for MDXG. As a fundamental investor, I make forward forecast based on an understanding of historical data. Below are my updated numbers: Millions

    Date. Sales. Fair price/Share

    12/21. 535. 24

    12/22. 748. 34

    12/23. 1400. 63

    12/24. 2100. 95

    12/25. 5000. 227

    The sales in the early years are what the market will be discounting in the future and reflected in the price. The later years are my sales forecast! The company will be bought out for 175 to 250 per share between 2024 and 2025’ Happy hunting!

    ... liegen lassen und abwarten